{"id":5976,"date":"2021-03-05T22:48:58","date_gmt":"2021-03-06T06:48:58","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=5976"},"modified":"2021-03-05T22:48:58","modified_gmt":"2021-03-06T06:48:58","slug":"tocilizumab-plus-standard-care-versus-standard-care-in-patients-in-india-with-moderate-to-severe-covid-19-associated-cytokine-release-syndrome-covintoc-an-open-label-multicentre-randomised-contr","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/05\/tocilizumab-plus-standard-care-versus-standard-care-in-patients-in-india-with-moderate-to-severe-covid-19-associated-cytokine-release-syndrome-covintoc-an-open-label-multicentre-randomised-contr\/","title":{"rendered":"Tocilizumab plus Standard Care versus Standard Care in Patients in India with Moderate to Severe COVID-19-Associated Cytokine Release Syndrome (COVINTOC): An Open-Label, Multicentre, Randomised, Controlled, Phase 3 Trial"},"content":{"rendered":"<ul>\n<li>A multi-center, phase-3, randomized trial among patients (n=180) with moderate to severe COVID-19 conducted at 12 hospitals across India of the anti-IL-6 receptor monoclonal antibody treatment tocilizumab found no significant difference in the proportion of patients with progressive COVID-19 up to day 14 between the treatment group compared to standard care group (9% vs 13%). No significant difference between the two groups was observed in the secondary endpoints, as well as the proportion of patients experiencing adverse events, serious adverse events, or death.<\/li>\n<\/ul>\n<p><i>Soin et al.\u00a0(Mar 4, 2021). Tocilizumab plus Standard Care versus Standard Care in Patients in India with Moderate to Severe COVID-19-Associated Cytokine Release Syndrome (COVINTOC): An Open-Label, Multicentre, Randomised, Controlled, Phase 3 Trial. The Lancet Respiratory Medicine. <\/i><a href=\"https:\/\/www.thelancet.com\/journals\/lanres\/article\/PIIS2213-2600(21)00081-3\/fulltext\">https:\/\/www.thelancet.com\/journals\/lanres\/article\/PIIS2213-2600(21)00081-3\/fulltext<\/a><span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A multi-center, phase-3, randomized trial among patients (n=180) with moderate to severe COVID-19 conducted at 12 hospitals across India of the anti-IL-6 receptor monoclonal antibody treatment tocilizumab found no significant difference in the proportion of patients with progressive COVID-19 up to day 14 between the treatment group compared to standard care group (9% vs 13%)&#8230;.<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/05\/tocilizumab-plus-standard-care-versus-standard-care-in-patients-in-india-with-moderate-to-severe-covid-19-associated-cytokine-release-syndrome-covintoc-an-open-label-multicentre-randomised-contr\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-5976","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=5976"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5976\/revisions"}],"predecessor-version":[{"id":5977,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5976\/revisions\/5977"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=5976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=5976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=5976"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=5976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}